NUCLEAR ONCOLOGY UK LTD.


Directors	MULHOLLAND, Nicholas James
	MULHOLLAND, Nicola Jane Reardon, Dr


Registered Address	C/O Balancia Accountancy Limited
	One Elmfield Park
	Bromley
	BR1 1LU


Registered Number	14179699 (England and Wales)

Balance Sheet as at
31 December 2025

	Notes	31 Dec 2025		30 Jun 2024
		£	£	£	£
Fixed assets
Tangible assets	3		61,475		-
			61,475		-
Current assets
Debtors	4	50,000		-
Cash at bank and on hand		23,162		4,120
		73,162		4,120
Creditors amounts falling due within one year	5	(21,829)		(11,868)
Net current assets (liabilities)			51,333		(7,748)
Total assets less current liabilities			112,808		(7,748)
Net assets			112,808		(7,748)
Capital and reserves
Called up share capital			5		5
Profit and loss account			112,803		(7,753)
Shareholders' funds			112,808		(7,748)

The company was entitled to exemption from audit for this reporting period under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.
The directors have chosen to not file a copy of the company’s profit and loss account under section 444 (5A) Companies Act 2006.

The financial statements were approved and authorised for issue by the Board of Directors on 25 September 2026, and are signed on its behalf by:

MULHOLLAND, Nicholas James
Director
Registered Company No. 14179699

NUCLEAR ONCOLOGY UK LTD.

Notes to the Financial Statements
for the period ended 31 December 2025

1.	Accounting policies

	Statutory information
	The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

	Statement of compliance
	The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.

	Going concern
	After reviewing the company's forecasts and projections, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis of accounting in preparing its financial statements.

	Revenue from sale of goods
	Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.

Revenue from sale of goods

Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.

	Foreign currency translation
	Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.

Foreign currency translation

Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.

	Tangible fixed assets and depreciation
	All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Tangible fixed assets and depreciation

All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:


		Straight line (years)
	Plant and machinery	4
	Office Equipment	4

2.	Average number of employees


		2025		2024
	Average number of employees during the year	2		2

3.	Tangible fixed assets

	Plant & machinery	Office Equipment	Total
	£	£	£
Cost or valuation
Additions	88,000	10,000	98,000
At 31 December 25	88,000	10,000	98,000
Depreciation and impairment
Charge for year	33,000	3,525	36,525
At 31 December 25	33,000	3,525	36,525
Net book value
At 31 December 25	55,000	6,475	61,475
At 30 June 24	-	-	-

4.	Debtors: amounts due within one year

	2025	2024
	£	£
Other debtors	50,000	-
Total	50,000	-

5.	Creditors: amounts due within one year

	2025	2024
	£	£
Taxation and social security	20,329	-
Other creditors	1,500	11,868
Total	21,829	11,868

6.	Directors advances, credits and guarantees
	Included within other debtors is an amount of £50,000 (2024: £10,897 owed to) the company owed by the directors.

7.	Controlling party
	The ultimate controlling party is the directors, jointly.

8.	Change in reporting period and impact on comparability
	These financial statements are prepared for the period from 1 July 2024 to 31 December 2025 for Nuclear Oncology UK Ltd. As a result of this, the comparative amounts presented in the financial statements (including the related notes) are not entirely comparable.